Table 1. Baseline characteristics of the included studies.
| Study | Journal | Type of Study | No. of pts (total, Exp vs Con) | pts population | Tumor stage | Treatment (Exp vs Con) | Bev schedule (cycles) | Primary end point (Exp vs Con) |
|---|---|---|---|---|---|---|---|---|
| ARTemis,2015,FP | Lancet Oncology | phase III, RCT, open label | 800,399 vs 401 | HER2(-) EBC | T>2cm | Bev+D-FEC vs D-FEC | 15 mg/kg iv, q3w(×4) | tpCR, 22% vs 17% |
| AVATAXHER, 2014,FP | Lancet Oncology | phase II,non-comparative RCT | 73,48 vs 25 | HER2(+) EBC | II-III | TH+bev vs TH | 15 mg/kg iv, q3w(×4) | pCR, 43.8% vs 24.0% |
| CALGB 40603,2014,FP | JCO | phase II, randomized 2×2 factorial, open label | 443,222 vs 221 | Operable,untreated,TNBC | II-III | wP→ddAC + Bev vs wP→ddAC; wPCb→ddAC + Bev vs wPCb→ddAC | 10 mg/kg iv, q2w(×9) | pCR, 59% vs 48% |
| Geparquinto,2012,FP | NEJM | phase III, RCT | 1948,974 vs 974 | untreated non-metastatic HER2(-) EBC | T1-T4d | EC→T+bev vs EC→T | 15 mg/kg iv, q3w(×8) | pCR, 18.4% vs 14.9% |
| NSABP B-40,2012,FP | NEJM | phase III, RCT | 1206,604 vs 602 | operable HER2(-) | I-III | T→AC+bev vs T→AC; TX→AC+bev vs TX→AC; TG→AC+bev vs TG→AC | 15 mg/kg iv, q3w(×6) | pCR, 34.5% vs 28.2% |
| S0800,2014,AB | Cancer Research | phase II,RCT | 208,96 vs 112 | HER2(-) IBC/LABC | III-IV | wP→ddAC + Bev vs wP→ddAC; ddAC→wP+bev vs ddAC→wP | NR | tpCR, 38% vs 21% |
| ABCSG-32,2014,AB | Cancer Research | phase II,RCT | 100,51 vs 49 | HER2(+) EBC | NR | TH+bev vs TH; THN+bev vs THN | 15 mg/kg | tpCR, 57% vs 49% |
| Hurvitz et al., 2012,AB | Cancer Research | RCT | 58,30 vs 28 | HER2(-),LABC | II-III, T>3cm | TAC+bev vs TAC | 15 mg/kg (×6) | tpCR, 13% vs 19% |
No.,number; Pts: patients;Exp, experimental arm; Con, control arm; FP, full paper; AB, abstract; RCT, randomized controlled trial; HER2, human epidermal growth factor receptor-2; EBC, early breast cancer; TNBC, triple-negative breast cancer; IBC, inflammatory breast cancer LABC, locally advanced breast cancer; pCR, pathological complete response; tpCR, total pathological complete response; NR: not reported; Bev, bevacizumab; T, docetaxel; C, cyclophosphomide; Cb, carboplatin; E, epirubicin; A, doxorubicin; F, fluorouracil; G, gemcitabine; X, capecitabine; H, trastuzumab; P, paclitaxel; wP, weekly paclitaxel; N, non-pegylated liposomal doxorubicin